Tissue factor expression and tumor-infiltrating T lymphocytes in ovarian carcinomas and their association with venous thromboembolism.


Journal

Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 09 09 2020
accepted: 15 01 2021
pubmed: 10 2 2021
medline: 19 1 2022
entrez: 9 2 2021
Statut: ppublish

Résumé

Ovarian cancer is a known risk factor of venous thromboembolism (VTE). Thrombogenic factor expression and lymphocytic infiltrate have been reported in endometriosis and ovarian cancers. We reviewed 30 cases of ovarian carcinomas (high grade serous carcinoma, 10; endometrioid carcinoma, 10; clear cell carcinoma (CCC), 10) and 16 endometriotic lesions. We immunohistochemically investigated the expressions of tissue factor (TF), podoplanin, P-selectin, and number of CD4 and CD8 positive lymphocytes in cancer tissue and endometriotic lesions, along with their relationship with VTE. The expression of TF was higher in CCC. The TF expression and the number of CD8 positive cells were higher in cancer tissues with VTE than in those without VTE. The podoplanin or P-selectin expression did not differ among histological types or between cases with and without VTE. Our results demonstrated a high TF expression and intraepithelial CD8 cells in CCC, which were associated with VTE. The results suggest that infiltrating lymphocytes may affect TF expression that, in turn, influences VTE.

Identifiants

pubmed: 33559251
doi: 10.1111/pin.13074
doi:

Substances chimiques

Membrane Glycoproteins 0
P-Selectin 0
PDPN protein, human 0
Thromboplastin 9035-58-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

261-266

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 15K09963
Organisme : Japan Society for the Promotion of Science
ID : 18K15083
Organisme : Japan Society for the Promotion of Science
ID : 19K07437
Organisme : Japan Society for the Promotion of Science
ID : 20K08085
Organisme : Grants-in-Aid for Scientific Research

Informations de copyright

© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Références

Cohen A, Lim CS, Davies AH. Venous thromboembolism in gynecological malignancy. Int J Gynecol Cancer 2017; 27: 1970-8.
Kato N. Pathology of clear cell carcinoma of the ovary: A basic view based on cultured cells and modern view from comprehensive approaches. Pathol Int 2020; 70: 591-601.
Grover SP, Mackman N. Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol 2018; 38: 709-25.
Uno K, Homma S, Satoh T et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 2007; 96: 290-5.
Krikun G, Schatz F, Taylor H, Lockwood CJ. Endometriosis and tissue factor. Ann NY Acad Sci 2008; 1127: 101-5.
Jander S, Sitzer M, Wendt A et al. Expression of tissue factor in high-grade carotid artery stenosis: Association with plaque destabilization. Stroke 2001; 32: 850-4.
Chen L, Lu Y, Chu Y, Xie J, Ding W, Wang F. Tissue factor expression in rheumatoid synovium: A potential role in pannus invasion of rheumatoid arthritis. Acta Histochem 2013; 115: 692-7.
Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 2015; 16: 807-20.
Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-43.
Mir Seyed Nazari P, Riedl J, Pabinger I, Ay C. The role of podoplanin in cancer-associated thrombosis. Thromb Res 2018; 164: S34-9.
Shamay Y, Elkabets M, Li H et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci Transl Med 2016; 8: 345ra87.
Riedl J, Ay C. Venous thromboembolism in brain tumors: Risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost 2019; 45: 334-41.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH. World Health Organization Classification of Tumours of Female Reproductive Organs, 4th edn. Lyon: International Agency for Research on Cancer, 2014.
Aman M, Ohishi Y, Imamura H et al. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma. Hum Pathol 2017; 64: 156-63.
Abu Saadeh F, Norris L, O'Toole S et al. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer - relationship with venous thrombosis risk. Thromb Res 2013; 132: 627-34.
Kato J, Okamoto T, Motoyama H et al. Interferon-gamma-mediated tissue factor expression contributes to T-cell-mediated hepatitis through induction of hypercoagulation in mice. Hepatology 2013; 57: 362-72.
Freeman ML, Panigrahi S, Chen B et al. CD8+ T-cell-derived tumor necrosis factor can induce tissue factor expression on monocytes. J Infect Dis 2019; 220: 73-7.
Yang Y, Stang A, Schweickert PG et al. Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1-dependent immune evasion. Cancer Res 2019; 79: 3417-30.
Oe S, Hasegawa K, Nagase S, Kato R, Torii Y, Udagawa Y. Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol 2010; 29: 405-10.
Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-8.

Auteurs

Toshihiro Gi (T)

Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Atsushi Yamashita (A)

Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Murasaki Aman (M)

Department of Diagnostic Pathology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Aya Kuwahara (A)

Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Department of Laboratory Center, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Yujiro Asada (Y)

Department of Pathology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Yasuyuki Kawagoe (Y)

Department of Obstetrics and Gynecology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Junji Onishi (J)

Department of Obstetrics and Gynecology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Hiroshi Sameshima (H)

Department of Obstetrics and Gynecology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Yuichiro Sato (Y)

Department of Diagnostic Pathology, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH